---
title: "Lysergide (DT120): Generalized anxiety disorder"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder. Clinical evidence covers Voyage, Panorama, MMED008, LSD-assist, LDA1, and MM-120-101. 820 evidence topics quoted from 199 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120): Generalized anxiety disorder

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Lysergide

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Generalized anxiety disorder

<a id="topic-1.1.1-1"></a>

##### Summary

The Mental and Substance Use Disorders Prevalence Study, which interviewed close to 5,700 U.S. adults aged 18 to 65 between October 2020 and October 2022, reported a past-year prevalence of generalized anxiety disorder (GAD) of 10.0% (95% CI 8.3% to 12.1%), approximately 20.2 million adults; its report names the study's conduct during the COVID-19 pandemic as the most obvious explanation for rates higher than in past nationally representative studies. Other estimates of 12-month prevalence are 2.7% of U.S. adults aged 18 or older in the National Comorbidity Survey Replication, 3.1% in a second analysis of that survey, and 2.1% in a third study, which reported a lifetime prevalence of 4.1%. In U.S. claims of adults engaging with the healthcare system, projected annual prevalence of diagnosed GAD rose from 5.4% in 2020 to 6.6% in 2023, and annual incidence of newly diagnosed GAD ranged from 2.1% to 2.3%. A further study reported a 1-year incidence of DSM-IV GAD of 1.12 per 100 person-years at risk. Definium Therapeutics states that GAD affects approximately 26 million U.S. adults, citing the prevalence study, Census data, and internal company estimates.

Over 12 years of follow-up, patients with GAD had a recovery probability of 0.58 and a recurrence probability after recovery of 0.45. Worldwide, lifetime comorbidity was 81.9%, with major depressive disorder in 52.6% of lifetime cases. Compared with the general population, mortality rate ratios in GAD were 1.62 (95% CI 1.35 to 1.93) for all causes and 2.55 (2.00 to 3.19) for unnatural causes.

In the 2022 US National Health and Wellness Survey, adjusted EQ-5D index scores were 0.80, 0.75, and 0.66 in mild, moderate, and severe GAD against 0.84 in controls. Adjusted total direct costs were $11,711 in diagnosed and $18,045 in undiagnosed GAD against $9,190 without GAD, and indirect costs were $7,507, $7,805, and $6,532, respectively. Of U.S. adults with past-year GAD, 32.3% had serious impairment.

Source: [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report); [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf); [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder); [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/); [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/); [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/); [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/); [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf); [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/); [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/); [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/); [Duong et al. (2024a)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/137867); [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843)

<a id="heading-1.1.2"></a>

#### 1.1.2 Lysergide Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: phase 3 trials Voyage and Panorama

Voyage and Panorama are phase 3, multicenter, randomized, double-blind, placebo-controlled trials of a single dose of DT120 orally disintegrating tablet (ODT) in adults with generalized anxiety disorder. Each has a 12-week Part A followed by a 40-week extension (Part B) in which participants could receive open-label DT120 ODT. All phase 3 results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.

Voyage randomized 214 participants 1:1 to DT120 ODT 100 µg (107) or placebo (107). The least squares (LS) mean change in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 was -11.6 with DT120 and -6.2 with placebo, a difference of -5.4 points (p<0.0001; standardized effect size d=0.81). Panorama randomized 245 participants 2:1:2 to DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97); the Week 12 change was -9.8 with 100 µg and -4.7 with placebo, a difference of -5.1 points (p<0.0001; d=0.64). The 50 µg arm was not designed or powered for statistical comparisons and had placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12. In both trials, each key secondary endpoint (Clinical Global Impression of Severity [CGI-S] change at Week 12 and Day 2, HAM-A change at Week 1) had a placebo-adjusted difference with p<0.0001. At Week 12, HAM-A response (improvement of 50% or more) occurred in 43% versus 16% of participants in Voyage and 32% versus 14% in Panorama, and remission (HAM-A of 7 or less) in 14% versus 4% and 15% versus 4%. In Panorama, 91% of participants given 50 µg and 95% given 100 µg correctly guessed assignment to drug. Part B results are interim analyses of partial data, with cutoffs of July 15, 2026 (Voyage) and August 11, 2026 (Panorama).

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-1.1.2-2"></a>

##### Summary: phase 2b trial MMED008

MMED008 was a phase 2b dose-finding trial conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023; its results were published online in September 2025 and posted on ClinicalTrials.gov. Of 198 participants randomized to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, 194 formed the full analysis set and 147 (74.2%) completed the study. Participants were tapered off anxiolytic and antidepressant treatments and received no study-related psychotherapy. In the primary MCP-Mod dose-response test of HAM-A change at Week 4, 5 of 6 candidate models exceeded the adjusted critical value of 2.032; LS mean differences from placebo were -5.0 points (95% CI, -9.6 to -0.4) with 100 µg and -6.0 points (95% CI, -9.8 to -2.0) with 200 µg, and the 25 µg (-1.2; 95% CI, -6.0 to 3.5) and 50 µg (-1.8; 95% CI, -7.6 to 4.0) groups did not reach statistical significance versus placebo. At Week 8 (key secondary), all 6 models exceeded the critical value of 2.041. A secondary analysis gave a Week 4 difference with 100 µg of -7.6 points (95% CI, -11.8 to -3.4; Cohen d = 0.88), the figure company announcements report, and a Week 12 difference of -7.7 points (95% CI, -12.6 to -2.8; P = .003); these secondary tests were not adjusted for multiple comparisons. At Week 12, HAM-A response occurred in 26 of 40 (65.0%), 25 of 40 (62.5%), and 12 of 39 (30.8%) participants given 100 µg, 200 µg, and placebo, and remission in 19 (47.5%), 18 (45.0%), and 8 (20.5%). Approximately 85% of participants correctly identified assignment to active treatment. The phase 3 trials use an ODT formulation in place of the phase 2b capsule.

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf); [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results); [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york); [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder); [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-1.1.2-3"></a>

##### Summary: academic LSD trials

Two trials in Switzerland, sponsored by University Hospital Basel and by the Multidisciplinary Association for Psychedelic Studies, tested oral LSD, given with talk therapy or psychotherapy, in participants with anxiety, with or without a life-threatening illness. NCT03153579 was a two-center, double-blind, placebo-controlled, two-period, random-order crossover trial with two sessions of LSD 200 μg or placebo per period and study visits consisting of talk therapy; 46 participants enrolled and 42 were analyzed. The State-Trait Anxiety Inventory Global (STAI-G) score decreased more with LSD up to 16 weeks after treatment (LS mean difference in change from baseline -16.2 [SE 5.8]; 95% CI, -27.8 to -4.5; d = -1.18; p = .007). A 2022 company announcement of an oral presentation reported STAI-G response (reduction of 30% or more) in 13 of 20 participants (65%) given LSD and 2 of 22 (9%) given placebo (p=0.003). At an uncontrolled follow-up 12 months after the end-of-study visit, STAI-G change from baseline was -21.6 (95% CI, -32.7 to -10.4) in the LSD-first group and -16.5 (95% CI, -26.2 to -6.8) in the placebo-first group, 11 participants (33%) were in anxiety remission, and post hoc tests found no difference between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The LDA1 pilot (NCT00920387) randomized 12 participants with anxiety associated with life-threatening diseases to LSD-assisted psychotherapy with LSD 200 μg (8) or an active placebo of LSD 20 μg (4), and analyzed 8 and 3. At 2 months, state anxiety decreased (p = 0.021; effect size 1.2) and trait anxiety showed a trend (p = 0.033; effect size 1.1); three of eight participants given 200 μg fell below the threshold of 40, and participants correctly guessed the dose in all 24 blinded sessions.

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/); [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders); [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579); [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/); [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-1.1.2-4"></a>

##### Summary: safety across studies

Adverse events in the phase 3 trials were collected under FDA psychedelic drug guidance, which includes expected effects characterized as positive, favorable, or neutral. In Voyage Part A, treatment-emergent adverse events (TEAEs) occurred in 106 of 107 participants (99%) given DT120 ODT 100 µg and 74 of 107 (69%) given placebo, and study drug-related TEAEs in 102 (95%) and 51 (48%); no DT120 event was severe, no DT120 participant had a serious adverse event (SAE) against 3 (3%) with placebo, and 1 DT120 participant (1%) discontinued for a TEAE. In Panorama Part A, TEAEs occurred in 91 of 96 (95%), 49 of 51 (96%), and 61 of 97 (63%) participants given 100 µg, 50 µg, and placebo; SAEs in 2 (2%), 1 (2%), and 1 (1%) were all deemed unrelated, and no TEAE led to discontinuation or death. The most common dosing-day TEAEs with 100 µg were illusion (75% in Voyage, 68% in Panorama), nausea (38%, 37%), euphoric mood (26%, 31%), and headache (24%, 24%). Neither trial reported suicidal or self-injurious behavior on the Columbia-Suicide Severity Rating Scale. As of September 14, 2026, 14 participants across all DT120 studies had a treatment-emergent SAE, 1 of them deemed treatment-related in Voyage Part B (rate approximately 1.45%); the sponsor stated that Part B safety data are expected to be shared in a future presentation. In the phase 2b trial, TEAEs occurred in 76.9% to 100% of lysergide groups and 56.4% of the placebo group, 98.5% of adverse events occurred on the dosing day, and the one SAE (a panic attack 97 days after dosing in the 50 µg group) was deemed unrelated. Across four DT120 studies, a safety analysis reported no treatment-related SAEs, hallucinogen persisting perception disorder, or deaths, and a thorough QT study did not show QT prolongation. In NCT03153579, 8 participants (19%) had transient, mild acute untoward effects and 1 (2%) a treatment-related SAE of acute transient anxiety; LDA1 reported no drug-related severe adverse events.

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Lysergide

<a id="topic-1.1.3-1"></a>

##### Summary

The sponsor states that the price of DT120 ODT has not been established and that reimbursement and coding for DT120 have yet to be established. On its third quarter 2026 earnings call, the sponsor stated a commercial pricing corridor of $30,000 to $75,000 per treatment course, based on preliminary payer feedback on the interventional psychiatry market, and related it to current payment for Spravato. Its 2026 corporate presentation estimates a $5B potential gross revenue opportunity from 100K patients treated (24 patients per year across ~4,000 interventional psychiatry clinics) at the midpoint of the Spravato surrogate pricing range, within a target population of 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments.

The pivotal trials required 8 hours of monitoring and clearance of an end-of-session checklist; average time to clearance was 5.8 hours in Emerge, 6.4 hours in Voyage, and 6.2 hours in Panorama (Part A). CPT codes 0820T, 0821T, and 0822T describe continuous in-person monitoring during psychedelic medication therapy, each per hour.

Analog evaluations: ICER estimated that 16% of eligible patients could be treated with esketamine at list price without exceeding its $819 million budget impact threshold, assigning a CPT 99214 visit to each dose for the 2-hour observation. For MDMA-assisted psychotherapy, at a $10,000 placeholder price per course, 1.91% of eligible patients could be treated over five years within the $735 million per year threshold.

Burden: in the 2022 US National Health and Wellness Survey (N=75,261), adjusted total direct costs were $11,711 for diagnosed and $18,045 for undiagnosed GAD versus $9,190 without GAD (both p<0.01). In the 2009 and 2010 Medical Expenditure Panel Survey, the annual incremental healthcare expenditure associated with anxiety disorders was $1657.52 per person.

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf); [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf); [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843); [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

- Burden and current therapy: past-year GAD prevalence among U.S. adults aged 18 to 65 was 10.0% (95% CI 8.3% to 12.1%). Up to 50% of patients respond inadequately to available agents, SSRI and SNRI discontinuation rates are 20% to 23%, and benzodiazepines carry a class boxed warning.
- Efficacy: in the phase 3 trials Voyage (214 participants) and Panorama (245 participants), a single dose of DT120 ODT 100 µg reduced the Week 12 HAM-A total score by 5.4 and 5.1 points more than placebo (both p<0.0001). These are company topline disclosures; one author states that adoption will depend on full peer-reviewed reporting. The published phase 2b trial (198 participants, capsules) reported a Week 4 difference of -5.0 points (95% CI, -9.6 to -0.4) with 100 µg.
- Safety: with 100 µg versus placebo, TEAEs occurred in 99% versus 69% of participants in Voyage and 94.8% versus 62.9% in Panorama, predominantly on the dosing day. As of September 14, 2026, 14 participants across all DT120 studies had a treatment-emergent serious adverse event, 1 deemed treatment-related.
- Regulatory status: not approved; Breakthrough Therapy designation for GAD (March 2024); NDA filing anticipated in the first half of 2027.
- Monitoring and scheduling: the pivotal trials required 8 hours of monitoring and an end-of-session checklist, which the sponsor intends to inform a potential REMS. Lysergide is Schedule I and must be rescheduled by the DEA and states after approval.
- Economics: price not established; the sponsor stated a corridor of $30,000 to $75,000 per treatment course. The report holds no cost-effectiveness or budget impact model of DT120, only ICER evaluations of esketamine and MDMA-assisted psychotherapy.
- Evidence gaps: peer-reviewed phase 3 reports; functional unblinding (91% and 95% of Panorama participants given 50 µg and 100 µg guessed assignment to drug); active comparators; durability and retreatment beyond 12 weeks (Part B data are open-label and interim); capsule to ODT bridging; registered quality of life outcomes; Part B safety data; and excluded populations.

Source: [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf); [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report); [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/); [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/); [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class); [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights); [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110); [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf); [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
